Innovative Exosome-Based Combination Therapy Offers New Hope for Treating Metabolic Liver Disease MASH
Researchers from Daegu Gyeongbuk Institute of Science and Technology (DGIST), led by Professor Yea Kyungmoo, have developed a groundbreaking exosome-based drug delivery system aimed at effectively treating metabolic dysfunction-associated steatohepatitis (MASH). This complex, currently incurable liver disease often coexists with obesity and diabetes, posing significant treatment challenges. The team's innovative approach involves engineering extracellular vesicles, or exosomes, to carry therapeutic agents directly to liver tissues.
Exosomes are natural particles produced by cells that transport proteins, lipids, and genetic materials, playing essential roles in cell communication. Their inherent biocompatibility, low toxicity, and minimal side effects make them promising carriers for targeted drug delivery, especially compared to traditional lipid-based systems.
The engineered exosomes are designed to address the key pathological mechanisms of MASH by simultaneously regulating metabolic abnormalities, inflammation, and fibrosis. The surface of these exosomes is modified to display Fibroblast Growth Factor 21 (FGF21), a potent protein that enhances fat burning. Inside, they carry microRNA-223, which effectively modulates inflammation and fibrosis. This dual-function system enables precise delivery to liver tissues, maximizing therapeutic effects.
This innovative strategy marks the first time an exosome-based combination treatment has been proposed for MASH, showcasing potential advantages over conventional therapies that often target single pathways and face issues like adverse cardiovascular effects or long-term safety concerns. The research team aims to establish scalable production methods to facilitate future drug development and clinical application.
The study, published in the journal Biomaterials, underscores the potential of bioengineered exosomes as a versatile platform for tackling complex metabolic diseases. As MASH represents a significant unmet medical need, this novel approach opens new avenues for safer and more effective treatments.
For more details, see the full publication: Hanchae Cho et al, "Engineered extracellular vesicles with surface FGF21 and enclosed miR-223 for treating metabolic dysfunction-associated steatohepatitis," Biomaterials, 2025. DOI: 10.1016/j.biomaterials.2025.123321
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Massive Recall of Over 32,000 Pounds of Meat Due to False USDA Inspection Labels
Over 32,000 pounds of meat have been recalled nationwide due to false USDA inspection labels, affecting products from Sabrositos Hondurenos, LLC. Consumers are urged to check for recalls and avoid consuming affected meat products.
Understanding Why Gene Therapy May Be Less Effective in Women: Insights from Mouse Research
New research reveals that gene therapy can be less effective and more risky for women, especially older women, due to differences in immune system responses. Insights from mouse studies are paving the way for personalized treatment strategies.
Proximity to Golf Courses Associated with Increased Parkinson's Disease Risk
A recent study reveals a significant association between living near golf courses and an increased risk of Parkinson's disease, especially in regions with groundwater vulnerability due to pesticide use. This research emphasizes environmental factors' role in neurodegenerative diseases and urges protective measures for affected communities.
Rising Incidents of Cannabis-Induced Vomiting Among Youth Leading to ER Visits
The rise in heavy cannabis use among youth has led to an increase in cannabis hyperemesis syndrome cases, causing more ER visits and highlighting the need for better awareness and prevention efforts.